Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UK pharmaceutical firm Scancell is working with Framingham, Massachusetts-based GTC Biotherapeutics to establish an agreement for the potential clinical development of its SC101 anticancer monoclonal antibody.
Subscribe to our email newsletter
The firms will evaluate the expression of Scancell’s drug using GTC’s transgenic production platform.
GTC says its technology offers significant advantages for the development of proteins that are expected to be required in large commercial production quantities.
SC101 is designed to target Lewis y/b, a cell surface carbohydrate blood group antigen whose expression is very low in normal tissue but is over-expressed on breast, colorectal, endometrial, kidney, lung, pancreas and stomach tumors. Animal studies have demonstrated that tumor growth was inhibited by anti-Lewis y/b antibodies alone.